Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist

Sun,Ji‑Min; Wang,Chun‑Miao; Guo,Zeng; Hao,Yu‑Yu; Xie,Yang‑Jing; Gu,Jian; Wang,Ai‑Ling

doi:10.3892/mmr.2014.2988

Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist

Authors:
- Ji‑Min Sun
- Chun‑Miao Wang
- Zeng Guo
- Yu‑Yu Hao
- Yang‑Jing Xie
- Jian Gu
- Ai‑Ling Wang
View Affiliations

Affiliations: Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Emergency, The First People's Hospital of Hefei, Hefei, Anhui 230051, P.R. China, Department of Cardiology, The First People's Hospital of Hefei, Hefei, Anhui 230051, P.R. China
Published online on: November 20, 2014 https://doi.org/10.3892/mmr.2014.2988
Pages: 1845-1850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac hypertrophy is a compensatory mechanism that occurs in conjunction with cardiovascular diseases. Although hypertrophy of the myocardium provides certain benefits during the early stages of cardiovascular disease, prolonged hypertrophy is potentially harmful to the heart and can result in arrhythmia and heart failure. The aim of this study was to investigate whether an ATP‑sensitive K+ (KATP) channel agonist was capable of reducing isoproterenol (Iso)‑induced cardiac hypertrophy and modulating myocardial connexin43 (Cx43) expression. Fifty male Sprague Dawley rats were randomly assigned to five groups: Normal, vehicle, nicorandil, glibenclamide and nicorandil plus glibenclamide. Rats in the four treatment groups received Iso injection for seven days, followed by administration with saline, nicorandil, glibenclamide or a combination of nicorandil and glibenclamide, respectively, for four weeks. Cardiac hypertrophy was then evaluated by measuring body weight, heart weight and left‑ventricular weight, and plasma B‑type natriuretic peptide levels were evaluated by ELISA. Immunocytochemistry and a reverse transcription‑polymerase chain reaction were performed to detect the spatial distribution and gene expression of myocardial Cx43, respectively. The KATP channel agonist nicorandil markedly attenuated the degree of myocardial hypertrophy induced by Iso as compared with the vehicle group. Myocardial Cx43 expression was significantly decreased and redistributed following cardiac hypertrophy. The decrease and redistribution of Cx43 was reduced following treatment with the KATP channel agonist nicorandil. Addition of the KATP channel blocker glibenclamide eliminated the beneficial effects of nicorandil against hypertrophy and on connexin43. In conclusion, the present study indicated that chronic use of KATP channel agonists following cardiac hypertrophy can attenuate ventricular remodeling and upregulate the expression level and spatial distribution of Cx43.

View Figures

View References

1	Weber KT, Anversa P, Armstrong PW, et al: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 20:3–16. 1992. View Article : Google Scholar : PubMed/NCBI
2	Verdecchia P, Carini G and Circo A; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 38:1829–1835. 2001. View Article : Google Scholar : PubMed/NCBI
3	Choudhary R, Mishra KP and Subramanyam C: Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant. Indian J Clin Biochem. 21:107–113. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rajesh KG, Sasaguri S, Suzuki R, Xing Y and Maeda H: Ischemic preconditioning prevents reperfusion heart injury in cardiac hypertrophy by activation of mitochondrial KATP channels. Int J Cardiol. 96:41–49. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lee TM, Lin MS and Chang NC: Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts. J Am Coll Cardio. 51:1309–1318. 2008. View Article : Google Scholar
6	Ennis IL, Escudero EM, Console GM, et al: Regression of isoproterenol-induced cardiac hypertrophy by Na⁺/H⁺ exchanger inhibition. Hypertension. 41:1324–1329. 2003. View Article : Google Scholar : PubMed/NCBI
7	Frohlich ED: State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 34:782–789. 1999. View Article : Google Scholar : PubMed/NCBI
8	Joyner RW: Effects of the discrete pattern of electrical coupling on propagation through an electrical syncytium. Circ Res. 50:192–200. 1982. View Article : Google Scholar : PubMed/NCBI
9	Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI and Gutstein DE: Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res. 95:1035–1041. 2004. View Article : Google Scholar : PubMed/NCBI
10	Boengler K, Dodoni G, Rodriguez-Sinovas A, et al: Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res. 67:234–244. 2005. View Article : Google Scholar : PubMed/NCBI
11	Roell W, Lewalter T, Sasse P, et al: Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature. 450:819–824. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rottlaender D, Boengler K, Wolny M, et al: Connexin 43 acts as a cytoprotective mediator of signal transduction by stimulating mitochondrial KATP channels in mouse cardiomyocytes. J Clin Invest. 120:1441–1453. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wang A, Chen F, Xie Y, Guo Z and Yu Y: Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown). 13:511–515. 2012. View Article : Google Scholar
14	de Lemos JA, McGuire DK and Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet. 362:316–322. 2003. View Article : Google Scholar : PubMed/NCBI
15	Tang Y, Wang M, Le X, et al: Antioxidant and cardioprotective effects of Danshensu (3-(3,4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats. Phytomedicine. 18:1024–1030. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pfeffer MA and Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 81:1161–1172. 1990. View Article : Google Scholar : PubMed/NCBI
17	Sakai K: Nicorandil: animal pharmacology. Am J Cardiol. 63:2J–10J. 1989. View Article : Google Scholar : PubMed/NCBI
18	Lee TM, Lin CC, Lien HY and Chen CC: K ATP channel agonists preserve connexin43 protein in infarcted rats by a protein kinase C-dependent pathway. J Cell Mol Med. 16:776–788. 2012. View Article : Google Scholar
19	Guéant Rodriguez RM, Spada R, Pooya S, et al: Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol. 167:768–775. 2013. View Article : Google Scholar
20	Swedberg K, Cleland J, Dargie H, et al: Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 26:1115–1140. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kimura T, Kitamura H, Inoue K, et al: Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease. Clin Exp Nephrol. 15:854–860. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kanno S and Saffitz JE: The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol. 10:169–177. 2001. View Article : Google Scholar : PubMed/NCBI
23	Egashira K, Nishii K, Nakamura K, Kumai M, Morimoto S and Shibata Y: Conduction abnormality in gap junction protein connexin45-deficient embryonic stem cell-derived cardiac myocytes. Anat Rec A Discov Mol Cell Evol Biol. 280:973–979. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wang Y and Hill JA: Electrophysiological remodeling in heart failure. J Mol Cell Cardiol. 48:619–632. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ohara T, Ohara K, Cao JM, et al: Increased wave break during ventricular fibrillation in the epicardial border zone of hearts with healed myocardial infarction. Circulation. 103:1465–1472. 2001. View Article : Google Scholar : PubMed/NCBI
26	Naitoh K, Ichikawa Y, Miura T, et al: MitoK_ATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res. 70:374–383. 2006. View Article : Google Scholar : PubMed/NCBI
27	Amino M, Yoshioka K, Tanabe T, et al: Heavy ion radiation up-regulates Cx43 and ameliorates arrhythmogenic substrates in hearts after myocardial infarction. Cardiovasc Res. 72:412–421. 2006. View Article : Google Scholar : PubMed/NCBI
28	Döring G: Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 20(Suppl 3): S74–S81. 1992. View Article : Google Scholar : PubMed/NCBI
29	The SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol. 2:213–217. 1999.
30	Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O and de Divitiis M: A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther. 7:119–123. 1993. View Article : Google Scholar : PubMed/NCBI
31	Zhu WL, Shan YD, Guo JX, et al: Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J. 71:826–833. 2007. View Article : Google Scholar : PubMed/NCBI
32	Baines CP, Liu GS, Birincioglu M, Critz SD, Cohen MV and Downey JM: Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am J Physiol. 276:H1361–H1368. 1999.PubMed/NCBI
33	Sugimoto K, Ito H, Iwakura K, et al: Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J. 67:295–300. 2003. View Article : Google Scholar : PubMed/NCBI
34	Garlid KD, Paucek P, Yarov-Yarovoy V, et al: Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K⁺ channels. Possible mechanism of cardioprotection. Circ Res. 81:1072–1082. 1997. View Article : Google Scholar : PubMed/NCBI